ADR Biomedical Holdings Inc. (TYO:3750)
Japan · Delayed Price · Currency is JPY 785.00
+10.00 (1.29%)
Aug 27, 2026, 2:38 PM JST
ADR Biomedical Holdings Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 101 | 50 | 122 | 1,560 | 2,144 | 1,335 | |
Revenue Growth | 13.48% | -59.02% | -92.18% | -27.24% | 60.60% | -3.82% |
Cost of Revenue | 45 | 41 | 129 | 268 | 876 | 476 |
Gross Profit | 56 | 9 | -7 | 1,292 | 1,268 | 859 |
Selling, General & Admin | 593 | 586 | 549 | 1,506 | 1,783 | 1,085 |
Research & Development | 153 | 153 | 202 | 351 | - | - |
Other Operating Expenses | 43 | 43 | - | - | - | - |
Operating Expenses | 923 | 916 | 800 | 2,065 | 2,063 | 1,321 |
Operating Income | -867 | -907 | -807 | -773 | -795 | -462 |
Interest Expense | -71 | -18 | -82 | -153 | -129 | -93 |
Interest & Investment Income | - | -68 | 3 | -487 | 11 | 19 |
Currency Exchange Gain (Loss) | -3 | -2 | - | - | - | - |
Other Non Operating Income (Expenses) | 5 | 5 | 25 | 19 | 63 | 137 |
EBT Excluding Unusual Items | -936 | -990 | -861 | -1,394 | -850 | -399 |
Gain (Loss) on Sale of Investments | - | - | -67 | - | -107 | 299 |
Gain (Loss) on Sale of Assets | - | - | -51 | 688 | - | - |
Asset Writedown | -20 | -20 | -1,173 | -336 | -205 | - |
Legal Settlements | - | - | - | - | - | -3 |
Other Unusual Items | 400 | 614 | - | 30 | -3 | 37 |
Pretax Income | -556 | -396 | -2,152 | -1,012 | -1,165 | -66 |
Income Tax Expense | 2 | - | -12 | -1,150 | -106 | 11 |
Earnings From Continuing Operations | -558 | -396 | -2,140 | 138 | -1,059 | -77 |
Net Income | -558 | -396 | -2,140 | 138 | -1,059 | -77 |
Net Income to Common | -558 | -396 | -2,140 | 138 | -1,059 | -77 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | 9 |
Shares Change | -0.00% | -0.00% | -0.34% | 0.34% | 1.12% | 7.89% |
EPS (Basic) | -62.50 | -44.35 | -239.69 | 15.46 | -118.61 | -8.72 |
EPS (Diluted) | -62.50 | -44.35 | -239.69 | 15.42 | -118.61 | -8.72 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -784 | -995 | -1,169 | -197 | -367 |
Free Cash Flow Per Share | - | -87.81 | -111.44 | -130.49 | -22.06 | -41.56 |
Gross Margin | 55.45% | 18.00% | -5.74% | 82.82% | 59.14% | 64.34% |
Operating Margin | -858.42% | -1814.00% | -661.48% | -49.55% | -37.08% | -34.61% |
Profit Margin | -552.48% | -792.00% | -1754.10% | 8.85% | -49.39% | -5.77% |
Free Cash Flow Margin | - | -1568.00% | -815.57% | -74.94% | -9.19% | -27.49% |
EBITDA | - | -858 | -758 | -520 | -465 | -142 |
EBITDA Margin | - | - | - | -33.33% | -21.69% | -10.64% |
D&A For EBITDA | - | 49 | 49 | 253 | 330 | 320 |
EBIT | -867 | -907 | -807 | -773 | -795 | -462 |
EBIT Margin | - | - | - | -49.55% | -37.08% | -34.61% |